Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD2 | Q9Y5L3 | 3/20 | 0.78 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210991 | 1.00 | ENTPD2 (0.78) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 | |
| SCHEMBL3027286 | 0.95 | ENTPD2 (0.70) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 | |
| SCHEMBL14383976 | 0.95 | ENTPD2 (0.70) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 | |
| SCHEMBL14387175 | 0.95 | ENTPD2 (0.70) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 | |
| SCHEMBL13210985 | 0.95 | ENTPD2 (0.70) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 | |
| SCHEMBL13211037 | 0.91 | ENTPD2 (0.74) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 | |
| SCHEMBL3014865 | 0.90 | ENTPD2 (0.77) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 | |
| SCHEMBL13210984 | 0.90 | ENTPD2 (0.77) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 | |
| SCHEMBL13210980 | 0.88 | ENTPD2 (1.00) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 | |
| SCHEMBL14384424 | 0.88 | ENTPD2 (1.00) | ENTPD2ENTPD1P2RY14P2RY6P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2019834-B1 | ECTONUCLEOTIDASE INHIBITORS | UNIV BONN (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | ENTPD2 10/4885ENTPD1 3/4885P2RY14 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.